RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with
cancer that has recurred following bone marrow or peripheral stem cell transplantation.
PURPOSE: Phase II trial to study the effectiveness of donated white blood cells in treating
patients who have relapsed cancer following transplantation of donated bone marrow or
peripheral stem cells.
OBJECTIVES: I. Offer donor lymphocyte infusion as adoptive immunotherapy in patients with
relapsed malignancies after allogeneic bone marrow or peripheral blood stem cell
transplantation and who are not eligible for other FHCRC protocols.
OUTLINE: Patients with rapidly progressive disease receive reinduction chemotherapy and
radiotherapy prior to study therapy. Donor lymphocyte infusions (DLI) begin after recovery
from chemotherapy or sooner, if clinically indicated. Patients receive 1 or more DLI from
the original donor. Patients are followed monthly for 3 months, then every 3-6 months for 9
PROJECTED ACCRUAL: An unlimited number of patients will be accrued for this study.
DISEASE CHARACTERISTICS: Diagnosis of relapsed malignancy after allogeneic transplantation
Rapidly progressive malignancies (acute leukemias) should receive induction chemotherapy
or radiotherapy prior to this study Persistent donor cells Must be able to tolerate a
taper of steroids to a dosage of no greater than 0.25 mg/kg/day and be off all other
immunosuppressive therapy for 2 weeks without significant flare of graft vs host disease
(GVHD) No grade II-IV acute GVHD or extensive chronic GVHD Same donor as for prior
PATIENT CHARACTERISTICS: Age: 1 to 70 Performance status: Karnofsky 30-100% Life
expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
specified Other: HIV negative
PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See
Disease Characteristics Endocrine therapy: See Disease Characteristics At least 1 week
since immunosuppressive therapy for advanced malignancy At least 2 weeks since
immunosuppressive therapy for nonadvanced malignancy Radiotherapy: See Disease
Characteristics Surgery: Not specified